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Abstract
Background:  The identification of poor medicinal adherence is difficult because direct
observation of medication use is usually impractical. Up to 50% of individuals on chronic therapies
may not be taking their medication as prescribed. This study is one of the first to explore possible
risk factors for over-reporting of antihypertensive adherence using electronic medication
monitoring.
Methods: The adherence of 286 individuals on single-drug antihypertensive therapy in a large
managed care organization was electronically monitored for approximately three months.
Questionnaires on socioeconomic background, adherence to therapy, health beliefs, and social
support before and after adherence monitoring were completed. Over-reporting of
antihypertensive adherence was assessed by comparing the self-reported frequency of
noncompliance with that determined from electronic dosing records. Risk factors for over-
reporting were identified by contingency table analysis and step-wise logistic regression.
Results: Although only 21% of participants acknowledged missing doses on one or more days per
week, electronic monitoring documented nonadherence at this or a higher level in 42% of
participants. The following variables were associated with over-reporting: >1 versus 1 daily dose
(OR = 2.58; 95% CI = 1.50–4.41; p = .0006), lower perceived health risk from nonadherence (OR
= 1.35; 95% CI = 1.10–1.64; p = .0035), and annual household income of <$15,000 versus >$30,000
(OR = 2.64; 95% CI = 1.13–6.18; p = .025).
Conclusions:  Over-reporting of adherence may be affected by factors related to dosing
frequency, health beliefs and socioeconomic status. This topic deserves further investigation in
other patient populations to elucidate possible underlying behavioral explanations.
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Background
Nonadherence to drug therapy can undermine the attain-
ment of therapeutic goals and contribute to the occur-
rence of medication side effects. Numerous adverse
clinical outcomes have been linked to nonadherence in-
cluding loss of blood pressure control [1,2], acute cardiac
events [3], renal transplant rejection [4], seizures [5], and
elevated Human Immunodeficiency Virus RNA levels [6].
Efforts to enhance medicinal adherence have met with
varying levels of success [7–9].
The detection of nonadherence to recommended treat-
ment can be problematic. In the clinical setting asking pa-
tients about their medication use is the most practical
means of ascertainment, but it is prone to inaccuracy
[10,11]. Strategies to increase the accuracy of screening for
nonadherence such as considering as nonadherent all
those who do not respond to therapy can augment sensi-
tivity. However, this unfairly mislabels some adherent pa-
tients as nonadherent [10]. In general, patients tend to
overestimate their adherence [8,12] and unless a patient is
not responding to therapy, it may be extremely difficult to
identify under-adherence. In research settings, pill counts,
drug levels, pharmacy dispensing records and electronic
medication monitors are available to measure medicinal
adherence but even some of these methods such as pill
counts may be susceptible to overestimating adherence
[8,13–15]. In many non-research situations these ap-
proaches may be difficult to implement due to their ob-
trusiveness, cost, or complexity.
Although studies have been conducted to identify risk fac-
tors for nonadherence itself [16], to the best of our knowl-
edge, only one previous study has examined possible risk
factors for over-reporting of adherence [17]. None has uti-
lized electronic medication monitors to study this area in-
volving antihypertensive medications. We consequently
undertook this present study among several hundred indi-
viduals who were receiving antihypertensive therapy in
order to explore which demographic, behavioral, and
clinical characteristics might be associated with over-re-
porting of adherence. The investigation was exploratory in
nature and was meant to identify possible leads for future
research. Electronic medication monitors were used to
track actual medication use against which the accuracy of
patient-reported adherence was determined.
Methods
Study population
The study design of this investigation has been described
previously in detail [15]. Briefly, the study was conducted
at Harvard Pilgrim Health Care (HPHC), a managed care
organization located in New England, among members
who were receiving antihypertensive medication from
1992 to 1994. Automated medical, pharmacy, and claims
records of the study population were screened to identify
potential study subjects and retrieve their outpatient
blood pressure data. Patients were eligible if they had
been HPHC members for at least three months, were at
least 18 years of age, and carried a diagnosis of hyperten-
sion. Only individuals on single-drug therapy for high
blood pressure were selected to simplify electronic adher-
ence monitoring.
Of 1,285 potentially eligible individuals, 330 consented
to participate and completed all phases of the study. The
majority of those who did not enroll in the study (71%)
declined mailed or telephone invitations to participate. In
addition, 42 subjects dropped out midway through the
study, and 44 individuals were later excluded because of
indications of improper use of their electronic medication
monitor such as removal of multiple doses at an opening
or incomplete closure of the medication vial. The remain-
ing 286 patients constituted the study population for this
investigation. Individuals who were eligible but did not
complete this investigation had a similar age, gender, and
blood pressure distribution as our study population.
However, calcium antagonists were prescribed slightly
more frequently (37% versus 24%) and angiotensin-con-
verting inhibitors less frequently (37% versus 49%) to in-
dividuals excluded from the final study population [15].
Collection of electronic and patient-reported adherence 
data
Individuals who consented to participate were mailed a
baseline questionnaire that covered their socioeconomic
background, medications (antihypertensive and other
drugs), adherence, health beliefs, health status (Medical
Outcomes Study, Short Form [SF-36]) [18], and social
support. Responses to the questionnaire were obtained by
telephone interview conducted by a research assistant.
Self-reported adherence during the monitoring period
was obtained using the following question, which was
adapted from the Brief Medication Questionnaire (Svars-
tad B., personal communication): While you were using the
special medication bottle, on how many days in an AVERAGE
WEEK did you forget to take a pill? 0, 1, 2, 3, 4, or 5+ days.
Our previous study [15] had indicated that responses to
this item (compared with 4 other adherence items) corre-
lated most closely with adherence as measured by elec-
tronic medication monitoring.
Social support was assessed using a 9-item inventory. The
inventory inquired about how often the participant could
rely on having someone to (1) listen to them, (2) accom-
pany them to the physician, (3) show affection to them,
(4) give them information, (5) provide them with advice
that they would want, (6) do things with them to turn
their minds to other things, (7) help with chores, (8)BMC Cardiovascular Disorders 2001, 1 http://www.biomedcentral.com/1471-2261/1/6
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share worries and fears with, and (9) do enjoyable things
with. Responses to each question were recorded on a Lik-
ert scale (1=none, 2=a little, 3=some, 4=most, or 5=all of
the time).
Electronic monitoring vials were dispensed with a fresh
supply of antihypertensive medication upon enrollment
in the study. Participants were instructed by pharmacists
to keep all their medication in the monitoring vial, use no
other source of antihypertensive medication, and to re-
move only one dose at a time from the monitoring vial.
Participants were informed of the purpose of the electron-
ic medication monitor.
Dosing events were recorded for approximately three
months using the Medication Event Monitoring System-4
(MEMS-4), manufactured by APREX Corporation, Union
City, CA. MEMS-4 is a microelectronic device housed
within a medication bottle cap that records the date and
time of each opening. The device blocks repeated open-
ings that occur within 15 minutes of each other to prevent
artifactual inflation of the number of dosing events. Data
were downloaded from the cap to a personal computer us-
ing a manufacturer-supplied communicator and software.
Two to three weeks after completion of electronic moni-
toring, a followup questionnaire was sent to participants
to update information on their socioeconomic status, pre-
scribed antihypertensive therapy, self-reported adherence
during the monitoring period, and health beliefs. Re-
sponses were once again obtained by telephone. All as-
pects of the study protocol were reviewed and approved
by the Human Studies Committee of Harvard Pilgrim
Health Care.
Data analysis
Due to the highly skewed distribution of questionnaire re-
sponses (only 4.5% of participants reported missing doses
2 or more days per week), the average number of days in
a week when participants missed a dose of antihyperten-
sive medication was dichotomized at 0 versus ≥ 1 day per
week. Setting the breakpoint between adherent and non-
adherent days at one day per week represents a frequency
of missed-dose days of 14.3% (1/7). MEMS-4 records
were used to derive the actual frequency of days when 1 or
more doses of antihypertensive medication were omitted.
Adherence was defined to be over-estimated by the pa-
tient if they reported an average frequency of nonadher-
ence of <1 day per week (i.e. <14.3%) while electronic
monitoring indicated a higher frequency of days with
missed doses (i.e. ≥ 14.3%).
Data analysis proceeded from an assessment of crude (un-
adjusted) associations with over-reporting of adherence to
step-wise logistic regression to identify which associations
remained after adjustment for other potential risk factors.
Six categories of variables were considered: (1) socioeco-
nomic and demographic background (age, gender, educa-
tion, marital status, employment, income); (2) clinical
features (blood pressure, duration of treatment, number
of doses per day); (3) clinician communication (previous
inquiry by clinician regarding medicinal adherence) (4)
health beliefs (perceived effectiveness of treatment and
susceptibility to adverse health outcomes); (5) health sta-
tus (SF-36 indices); and (6) social support (a summary
score derived from the 9-item support inventory). These
variables were chosen either because their information
might be obtainable or inferred by practicing clinicians, or
they had been evaluated in previous studies of adherence
behavior [8,9,19,20]. Chi-square or likelihood ratio tests
from logistic regression models were used to evaluate
crude associations between over-reporting and possible
predictor variables. In executing the stepwise logistic re-
gression procedure, a selection criterion of p ≤  .2 was se-
lected to allow for the evaluation of the joint effect of
multiple variables. The rejection criterion was also set rel-
atively high at p ≥  .1 to permit identification of all poten-
tial associations with over-reporting of adherence. As
described later in this paper, all variables that were ulti-
mately retained in the final logistic regression model am-
ply met these retention criteria. All data manipulations
and statistical analyses were conducted using SAS, release
6.12 (SAS Institute, Carey, NC).
Results
The study population was composed of 286 individuals
whose mean age was 55 years (range: 18–84 years). As list-
ed in the Table 1, approximately half were female, one
third Black, and two thirds had some college or graduate
level education. The mean (± standard deviation) systolic
and diastolic blood pressures in the previous year were
140.0(± 16.1)/86.3(± 10.4). Angiotensin converting en-
zyme inhibitors were the most commonly prescribed an-
tihypertensive agents (48%) followed by calcium
antagonists (22%), diuretics (16%), beta blockers (13%),
and other agents (1%). The median duration of antihyper-
tensive therapy prior to involvement in the study was
slightly greater than four years.
Average nonadherence was 16% among individuals who
reported that they were nonadherent <1 day a week com-
pared with 40% among individuals who reported more
frequent nonadherence. The Spearman correlation be-
tween reported and electronically measured adherence
was 0.34 (p-value =.0001). While only 21% of partici-
pants acknowledged missing doses one or more days per
week, electronic medication monitoring documented
nonadherence at this or greater levels in 42% of partici-
pants. Seventy-eight (27%) of the 286 participants over-
reported their actual adherence. As shown in Table 1, be-BMC Cardiovascular Disorders 2001, 1 http://www.biomedcentral.com/1471-2261/1/6
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ing unmarried (which included being widowed, separat-
ed, divorced, or never married; OR = 1.80; 95% CI = 1.06–
3.06;  p =.03), annual income of <$15,000 relative to
>$30,000 (OR = 2.66; 95% CI = 1.16–6.09; p =.02), pre-
scription of >1 dose per day (OR = 2.66 95% CI = 1.57–
4.51; p = .0003), and diminished perceived risk from non-
adherence (OR = 1.28 for a 1-level difference; 95% CI =
1.06–1.55; p = .01) were associated with over-reporting of
adherence in unadjusted analyses.
Step-wise logistic regression selected and retained being
prescribed >1 dose per day (OR = 2.58; 95% CI = 1.50–
Table 1: Distribution and crude odds ratios of possible risk factors for over-reporting of antihypertensive adherence
Variable Distribution Crude OR (95% CI); p-value
Demographic/Socioeconomic
Mean age in years (range) 55 (18–84) 1.01 (0.99–1.03) p = .23
Female 53% 1.29 (0.76–2.18) p = .26
Race
White 58% reference
Black 35% 1.35 (0.79–2.32) p = .28
Other 7% 1.56(0.55–4.48) p = .41
Marital status
Unmarried 51% reference
Married 49% 0.56 (0.33–0.95) p = .03
Mean years of education (range) 16 (9–23) 0.96 (0.89–1.03) p = .24
Employment
Working 71% reference
Retired 18% 1.46 (0.76–2.80) p = .25
Unemployed or other 11% 0.69 (0.27–1.78) p = .44
Income
>29,000 9% reference
$15,000–29,000 24% 1.55 (0.85–2.85) p = .16
<$15,000 61% 2.66(1.16–6.09) p = .02
Mean (Standard Deviation) Social Support Score (Range-9–45) 34.9 (8.6) 1.01 (0.98–1.04) p = .48
Clinical Parameters
Median years of treatment (interquartile range) 4.5 (2–10) 1.00 (1.00–1.00) p = .76
Mean (± s.d) systolic BP in previous year 140.0 (± 16.1) 0.98 (0.96–1.01) p = .15
Mean (± s.d) diastolic BP in previous year 86.3 (± 10.4). 0.97 (0.93–1.01) p = .10
Number of doses of antihypertensive medication per day ≤  1 85% reference
>1 15% 2.66 (1.57–4.51) p = .0003
Doctor did ask how well patient was taking medication 46% 0.71(0.42–1.19) p = .20
Mean (± s.d) Health Status Indices (Short Form-36)
Physical Function 82.5 (± 21.2) 1.00 (0.98–1.01) p = .39
Energy-Vitality 59.6 (± 19.8) 1.00 (0.98–1.01) p = .56
Social Function 85.4 (± 19.4) 1.00 (0.99–1.01) p = .98
Mental Health 76.5 (± 17.1) 1.00 (0.98–1.01) p = .80
General Health Perception 68.4 (± 19.2) 1.01 (0.99–1.02) p = .46
Role Physical 80.9 (± 33.9) 1.00 (0.99–1.01) p = .73
Role Emotion 82.1 (± 32.4) 1.00 (0.99–1.00) p = .27
Pain 71.8 (± 22.6) 1.01 (0.996–1.02) p = .22
Health Beliefs
Confidence in medication to control blood pressure
Very confident 66% reference
Not very confident 34% 0.89 (0.51–1.55) p = .68
Chance that something bad will happen if not taking medication
very unlikely 18%
fairly unlikely 14% 0.78 (0.65–0.94) p = .01
as likely to happen as not to happen 27% (for each change in level)
fairly likely 23%
very likely 16%BMC Cardiovascular Disorders 2001, 1 http://www.biomedcentral.com/1471-2261/1/6
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4.41; p = .0006), diminished health risk perception (OR =
1.35; 95% CI = 1.10–1.64; p = .0035), and annual income
of <$15,000 (OR = 2.64; 95% CI = 1.13–6.18; p = .025) in
that order. Lower mean systolic blood pressure in the year
prior to participation in the study was initially selected (p
= .12) but not retained in the final regression model. Mar-
ital status was not chosen by the step-wise procedure. Age,
gender, and race/ethnicity also were not associated (p
>.05) with over-reporting in both the crude and step-wise
logistic regression analyses. Including all variables with
crude associations (p ≤  .1) with over-reporting of adher-
ence (marital status, income, mean diastolic blood pres-
sure in the previous year, number of daily doses, and
perceived risk) in a single logistic regression model did
not materially affect our findings (results not shown). The
link between >1 daily dose and over-reporting of adher-
ence was blocked (OR = 1.38; 95% CI = 0.73–2.64; p =
.33) by adjusting for actual adherence as measured by
MEMS-4 in the final, selected model indicating that the as-
sociation between dosing frequency and over-reporting
was most likely mediated by actual adherence.
Discussion
The main purpose of this exploratory analysis was to iden-
tify potential risk factors for over-reporting of adherence.
We observed that frequent daily dosing, reduced risk per-
ception from nonadherence, and lower annual income
were associated with over-reporting in our study popula-
tion. Not surprisingly, less adherent individuals were also
more likely to over-report their adherence than other
more adherent individuals, a pattern that has been report-
ed by other investigators [8,12].
The exploratory nature of this investigation makes cau-
tious interpretation of our findings necessary. Multiple
comparisons were made in this study and consequently
the results may have been chance findings. Use of a very
conservative standard of significance based on the Bonfer-
roni adjustment would require a p-value of ≤  .002 (.05/23
where .05 represents the traditional standard of signifi-
cance and 23 the number of comparisons made). By these
criteria, only dosing frequency would still be considered
statistically significant.
The association between dosing frequency and over-re-
porting of adherence was apparently mediated by actual
adherence behavior because adjusting statistically for elec-
tronically measured adherence blocked this relationship.
This is not surprising because frequent dosing usually pre-
dicts lower adherence [5,21] and lower adherence is asso-
ciated with over-reporting. As a consequence, frequent
dosing would be expected to correlate with over-reporting
via its connection with actual adherence.
On a more conjectural level, the observed connection be-
tween decreased perception of health risk from nonadher-
ence and over-reporting of adherence may indicate that
health belief models that posit a direct relationship be-
tween perceived risk and adherence may also apply to the
accurate recollection of past medication use [22–25]. In
addition, the association with lower household income in
our study population may indicate that a more stressful if
not disorganized life situation, as suggested by lower soci-
oeconomic status, may increase the likelihood of inaccu-
rately believing that missed doses were taken.
Furthermore, some individuals may report what they be-
lieve that clinicians or researchers want to hear. This be-
havior might be more likely when the perceived difference
in power (as measured by wealth and income) is maxi-
mal.
Several factors that may contribute to the inaccurate re-
counting of adherence by patients were not evaluated in
this study. The research instruments did not cover partici-
pants' attitudes towards the healthcare system, their
healthcare providers, or the research staff involved in this
study. The quality of the patient-physician (and by exten-
sion the participant-researcher) relationship may have a
significant impact on what patients will discuss with their
healthcare provider [26]. Furthermore, formal psycholog-
Table 2: Cross-tabulation of self-reported versus actual adherence1
Actual Adherence2
Self-Reported Adherance Cell counts (%) <1 Day/Week ≥  1 Day /Week Row Totals (%)
<1 Day/Week 147 (51.4) 78 (27.3) 225 (78.7)
≥  1 Day/Week 18 (6.3) 43 (15.0) 61 (21.3)
Column Totals 
(%)
165 (57.7) 121 (42.3) 286 (100.0)
1Adherence defined as number of days when 1 or more doses were missed 2Electronically measured using MEMS-4BMC Cardiovascular Disorders 2001, 1 http://www.biomedcentral.com/1471-2261/1/6
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ical and cognitive testing were not performed on study
participants to permit evaluation of the effect of memory,
judgement, mood, and personality on adherence and the
accurate reporting of noncompliance.
Conclusions
This investigation is one of the first to evaluate possible
risk factors for over-reporting of adherence by patients.
The findings suggest that factors related to socioeconomic
status, the dosing regimen, and perceived risk from non-
adherence may influence how accurately patients recall
and report their adherence. Additional investigation will
be needed to confirm and extend these findings as well as
elucidate the possible underlying behavioral mechanisms
that are involved.
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